{"title":"Baxter Expands its Oncology Pipeline by Licensing European Rights to Onconova Therapeutics’ Rigosertib","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I9.1811","DOIUrl":null,"url":null,"abstract":"In return for US$50 M upfront and up to US$515 M in precommercialisation milestone payments, Baxter International has licensed European commercialisation rights to Onconova Therapeutics’ lead anticancer therapy rigosertib. The drug candidate is currently in Phase III development for myelodysplastic syndromes, for which it has been granted Orphan Drug Designation in the US and Europe, and is the subject of a Phase II/III study in pancreatic cancer. Baxter, which has an existing US$50 M equity position in Onconova, also has the option to develop rigosertib in additional indications.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"50 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I9.1811","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
In return for US$50 M upfront and up to US$515 M in precommercialisation milestone payments, Baxter International has licensed European commercialisation rights to Onconova Therapeutics’ lead anticancer therapy rigosertib. The drug candidate is currently in Phase III development for myelodysplastic syndromes, for which it has been granted Orphan Drug Designation in the US and Europe, and is the subject of a Phase II/III study in pancreatic cancer. Baxter, which has an existing US$50 M equity position in Onconova, also has the option to develop rigosertib in additional indications.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
